NCT00570635 - A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Gastrointestinal Stromal TumorsGastrointestinal Neoplasms

Interventions

DRUG

XL820

XL820 capsules administered orally as a single agent at a dose of 800 mg daily

DRUG

XL820

XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily

Trial Locations (3)

Park Ridge

Los Angeles

Boston